SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents.
DexCom reports quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue comes in at $994.2 million, which beat the analyst consensus estimate ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...
Dexcom, maker of popular diabetes management products, recently announced the layoff of 535 employees at its San Diego location as the company reportedly moves to centralize its United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback